CLVS News Alert Clovis Oncology Inc (CLVS) 54.58 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Clovis Oncology Inc (CLVS) 54.58 $CLVS

AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:48PM CST
AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian cancer.
AGN: 210.12 (+0.95), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.18 (-0.22), BIB: 122.51 (+3.83), INCY: 71.57 (+1.99), PFE: 31.42 (-0.03), IBB: 299.80 (+5.12), DRGS: 53.60 (unch), BIND: 5.73 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), ONTY: 1.89 (+0.01), ECYT: 6.33 (+0.24), BIS: 47.26 (-1.74), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), ARIA: 6.81 (+0.15), IRY: 47.28 (-0.01), IXJ: 100.54 (+0.55), FPRX: 26.12 (+0.07)

Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 20, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
IMDZ: 34.96 (+0.78), ANY: 5.99 (+0.36), SNCR: 43.24 (+0.21), CLVS: 54.58 (+0.43), CYAN: 7.00 (+0.50), RTRX: 12.92 (+0.19), RAVN: 25.52 (-0.07), RMTI: 8.41 (-0.07), DWCH: 9.08 (-0.07)

Foundation Medicine's Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology's PARP inhibitor, Rucaparib
Business Wire - Wed Nov 19, 5:05PM CST
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the presentation of new data from its ongoing collaboration with Clovis Oncology (NASDAQ: CLVS) to develop a novel companion diagnostic test to identify patients who have the potential to benefit from rucaparib, Clovis Oncology's poly (ADP-ribose) polymerase inhibitor (PARPi). These new data suggest that Foundation Medicine's novel companion diagnostic can identify both BRCA-mutant patients and non BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative.
FMI: 23.99 (-0.10), CLVS: 54.58 (+0.43)

Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients
Business Wire - Wed Nov 19, 5:01PM CST
--Overall response rate (ORR) of 70% in BRCA-mutant patients; responses observed in patients with both germline and somatic mutations
CLVS: 54.58 (+0.43)

CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Dr. Paul Nunzio DeSantis, Pharm.D - at Seeking Alpha - Wed Nov 19, 10:41AM CST

CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26)

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
at The Street - Wed Nov 19, 8:38AM CST
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26)

Clovis off premarket after report on CO-1686
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:21AM CST

CLVS: 54.58 (+0.43)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:14AM CST

SGYP: 3.08 (+0.12), ANV: 0.88 (+0.02), VIPS: 19.95 (+0.41), CLVS: 54.58 (+0.43), SUNE: 19.50 (+0.01), SNSS: 2.48 (-0.03), CLF: 6.06 (-0.09), GSAT: 2.97 (+0.03), EJ: 7.48 (+0.17), OPLK: 24.23 (-0.03), LITB: 6.30 (+0.10)

Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
Business Wire - Tue Nov 18, 5:36PM CST
--Median PFS of 10.4 months in clinical dose group; data continue to mature
CLVS: 54.58 (+0.43)

Clovis teams up with Glaxo on combo cancer therapy
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:20AM CST

CLVS: 54.58 (+0.43), GSK: 42.85 (+0.11)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST

URBN: 34.15 (-0.53), DHX: 10.28 (+0.08), ACT: 254.20 (-1.68), OME: 10.00 (+0.09), CLVS: 54.58 (+0.43), AVB: 166.95 (-1.27), PF: 35.32 (+0.13), RMTI: 8.41 (-0.07), GLW: 23.22 (+0.08), FOLD: 7.94 (+0.06)

Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
Business Wire - Mon Nov 17, 4:00PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in 1H 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).
CLVS: 54.58 (+0.43), GSK: 42.85 (+0.11)

Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
Business Wire - Wed Nov 12, 4:28PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rociletinib is the Company's novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M.
CLVS: 54.58 (+0.43)

Clovis Oncology's (CLVS) CEO Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:10PM CST

CLVS: 54.58 (+0.43)

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:40PM CST

CLVS: 54.58 (+0.43)

Clovis misses 3Q profit forecasts
Automated Insights - Thu Nov 06, 6:39PM CST
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $39.6 million in its third quarter.
CLVS: 54.58 (+0.43)

Clovis Oncology misses by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:00PM CST

CLVS: 54.58 (+0.43)

Clovis Oncology Announces Third Quarter 2014 Operating Results
Business Wire - Thu Nov 06, 3:01PM CST
--$278.3 million raised in September sale of senior convertible notes
CLVS: 54.58 (+0.43)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 22

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 92

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 11

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 57

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 239

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Charlotte's Web Moves Forward with AJA001 Autism Treatment Trial

Updated Category News Views 280

Charlotte's Web Progresses to Phase 2 in Autism Treatment Charlotte's Web Holdings, Inc. (TSX: CWEB) has announced an important step in the development of its botanical drug known as AJA001, aimed at treating symptoms associated with autism spectrum disorder (ASD). The U.S. Food and Drug Administration (FDA) has officially issued a green light for Charlotte's Web and its...

Continue Reading
Uptown Cheapskate and Kid to Kid Celebrate Monumental Growth

Updated Category News Views 257

Uptown Cheapskate and Kid to Kid Celebrate Monumental Growth Uptown Cheapskate and Kid to Kid have reached an amazing milestone, surpassing $300 million in system-wide sales during a recent year, showcasing a remarkable growth of over 20% compared to the previous year. This achievement is a testament to the increasing consumer demand for thrift shopping and the unique...

Continue Reading
Exploring the Thriving Landscape of Smart Wearables Market Trends

Updated Category News Views 146

Overview of the Smart Wearables Market Growth The Smart Wearables market is on an exciting upward trajectory, expected to surge from its valuation of USD 77.95 billion to an impressive USD 319.42 billion by 2032. With a robust compound annual growth rate (CAGR) of 19.34%, the sector reflects significant consumer interest and technological advancements. This remarkable...

Continue Reading
Exciting Partnership: Bass Pro Shops and the SMX League Unite

Updated Category News Views 239

Bass Pro Shops Teams Up With The SMX League Bass Pro Shops is set to become the official partner across the entire SMX racing calendar. One of the most thrilling events to look forward to is the Monster Energy SMX World Championship Final, which is scheduled to take place at Thunder Ridge, creating an exciting experience for fans. Venue Selection for The Championship...

Continue Reading
ADI Foundation Launches Innovative ADI Chain Mainnet and Token

Updated Category News Views 172

Exciting Developments from the ADI Foundation The ADI Foundation has recently launched the mainnet of ADI Chain along with its native ADI utility token. This significant step establishes a specialized Layer-2 blockchain aimed at enhancing operations for governments, regulated entities, and various real-world applications. By creating a tailored blockchain environment, the...

Continue Reading